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Abstract: Cells release extracellular vesicles (EVs) to communicate in a paracrine manner with other
cells, and thereby influence processes, such as angiogenesis. The conditioned medium of human
cardiac-derived adherent proliferating (CardAP) cells was recently shown to enhance angiogenesis.
To elucidate whether their released EVs are involved, we isolated them by differential centrifugation
from the conditioned medium derived either in the presence or absence of a pro-inflammatory
cytokine cocktail. Murine recipient cells internalized CardAP-EVs as determined by an intracellular
detection of human proteins, such as CD63, by a novel flow cytometry method for studying EV–cell
interaction. Moreover, endothelial cells treated for 24 h with either unstimulated or cytokine
stimulated CardAP-EVs exhibited a higher tube formation capability on Matrigel. Interestingly,
unstimulated CardAP-EVs caused endothelial cells to release significantly more vascular endothelial
growth factor and interleukin (IL)-6, while cytokine stimulated CardAP-EVs significantly enhanced
the release of IL-6 and IL-8. By nCounter® miRNA expression assay (NanoString Technologies) we
identified microRNA 302d-3p to be enhanced in unstimulated CardAP-EVs compared to their cytokine
stimulated counterparts, which was verified by quantitative polymerase chain reaction. This study
demonstrates that both CardAP-EVs are pro-angiogenic by inducing different factors from endothelial
cells. This would allow to select potent targets for a safe and efficient therapeutic application.
Keywords: extracellular vesicles; angiogenesis; VEGF; regeneration; cardiac therapy;
intracellular uptake
1. Introduction
Cell-cell communication between neighboring and distant cells is crucial for the survival of an
organism. It initiates essential processes, such as growth, differentiation or defense mechanisms against
pathogens. A direct communication between neighboring cells is ensured by structural connections
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between them, like tight junctions, while it is enabled in an indirect manner by releasing signaling
molecules into the extracellular space [1–5]. Those molecules can be used by the cell itself (autocrine)
or by cells in their more immediate vicinity as well as over greater distances (paracrine or endocrine
for hormones). Knowledge about mechanisms triggered by this cellular crosstalk can help to improve
or even to evolve new therapeutic approaches. For example, processes such as angiogenesis, are
highly desired to be enhanced for treating diseases, like those of the cardiovascular system [6,7].
In contrast, a rogue communication can affect the homeostasis of an organism and manifest diseases.
Malignant degenerated cells, for example, have altered their communication to facilitate the formation
of metastases and to evade immune responses [8,9].
In the last decades, extracellular vesicles (EVs) have been identified as a major paracrine mediator.
They contain a variety of signaling molecules, including diverse RNA types, such as messenger RNA or
micro RNA (miRNA), receptors, enzymes, and lipids. Three different types of EVs can be distinguished
by their biogenesis and diameter. Exosomes, the smallest subtype (diameter < 0.1 µm), are derived
intracellularly in so called multivesicular bodies, while microvesicles (diameter range = 1–0.1 µm) bud
directly from the cell membrane and apoptotic bodies (diameter > 1 µm) are formed by the disassembly
of apoptotic cells [10–15]. Recent in vitro and in vivo studies demonstrated that beneficial therapeutic
effects were initiated by EVs originating from regenerative cells of diverse sources [16–20]. A commonly
observed phenomenon was the pro-angiogenic effect of EVs derived from mesenchymal stromal cells
(MSCs) [21,22], endothelial cells [23,24], as well as cardiac derived cells [17,19,25]. However, not only
EVs from “therapeutic” cell sources but also EVs from cancer cells are able to enhance angiogenesis [26].
The potential mechanisms of action and molecules delivered by EVs that affect the vascular
development, growth and maturation have been recently reviewed [27]. Here, a wide spectrum of
molecules contained within EVs was described, ranging from growth factors, like vascular endothelial
growth factor (VEGF), to miRNAs, such as miRNA 126. Since the cellular milieu during the biogenesis
of EVs crucially affects their cargo composition, their biological effects can change subsequently.
MSC-EVs derived under limited oxygen concentration (hypoxia) showed superior pro-angiogenic
features compared to their counterparts derived under normoxia conditions [28–31]. Another important
environmental parameter is inflammation, which can be mimicked in the cell culture by supplementing
the media with pro-inflammatory cytokines. Endothelial cells treated with interleukin 3 (IL-3) released
EVs with superior pro-angiogenic capacity compared to their unstimulated counterpart as shown by
Lombardo et al. [23]. Several studies have predominantly investigated the role of cytokine stimulated
EVs derived from mesenchymal cells in the context of immunomodulation [32,33]. However, it is
not yet completely understood how an inflammatory microenvironment influences the angiogenic
features of mesenchymal or cardiac cell derived EVs [29,34]. To try and understand this, we isolated
EVs from the conditioned medium of human cardiac-derived adherent proliferating (CardAP) cells
that were cultured either in the presence or absence of a pro-inflammatory cytokine cocktail containing
IL-1 beta (IL-1β), interferon gamma (IFN-γ), and the tumor necrosis factor alpha (TNF-α). CardAP
cells were chosen as source of EVs, because the conditioned medium of this MSC-like cell type
already demonstrated to enhance tube formation capabilities of human umbilical vein endothelial
cells (HUVECs) [35]. Furthermore, CardAP cells displayed a set of other cardioprotective effects,
including immunomodulation and the improvement of heart functions in virus or angiotensin II
induced cardiovascular disease models [36–39]. Since we were already able to show that the immune
modulating effect of CardAP cells is partially facilitated by their released EVs [40], it would be of further
interest if the cardioprotective feature of enhancing angiogenesis is also facilitated by CardAP-EVs.
This knowledge would be useful for a future therapeutic cell-free approach for the treatment of
cardiovascular diseases by using CardAP-EVs. Therefore, we not only focused on the impact of
unstimulated and cytokine stimulated CardAP-EVs on HUVECs but also on their interaction with
possible cardiovascular target cells to evaluate them further as a tool for treating heart diseases.
In the present study, unstimulated as well as cytokine stimulated CardAP-EVs demonstrated
to enhance the tube formation capabilities of HUVECs. Interestingly, although both CardAP-EVs
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showed the same beneficial effect, the pro-angiogenic molecules released from HUVECs were different.
HUVECs treated with unstimulated CardAP-EVs released significantly more VEGF and IL-6, whereas
cytokine stimulated CardAP-EVs enhanced the release of IL-6 and IL-8 from HUVECs. Our results
indicate that this difference was due to an altered miRNA composition between unstimulated and
cytokine stimulated CardAP-EVs. Indeed, a potent VEGF inducing miRNA, namely miRNA302d-3p,
was found to be enriched in unstimulated CardAP-EVs in comparison to their cytokine stimulated
counterparts. Furthermore, we introduced a novel method to demonstrate the intracellular uptake
of CardAP-EVs by cardiac murine cells, which would additionally support the miRNA transfer into
recipient cells.
Overall, our results support that the inflammatory microenvironment during EV biogenesis
influences the content composition of CardAP-EVs and thereby mediate their general pro-angiogenic
feature via different pathways. Furthermore, the pro-angiogenic effect of CardAP-EVs would argue for
their suitability as a future therapeutic application to treat cardiovascular diseases.
2. Results
2.1. CardAP-EVs are Interacting with Cardiac Murine Cells
The size, phenotype and immune modulating capacity of CardAP-EVs has been recently
determined [40]. In this study, we focused on the interaction between CardAP-EVs and cardiovascular
target cells to determine their impact on angiogenesis as a means to further evaluate their potential
as a tool for treating heart diseases. First, CardAP-EVs were isolated by differential centrifugation
from the conditioned medium from CardAP cells cultured either in the presence or in the absence
of a pro-inflammatory cytokine cocktail containing 10 ng/mL of IFNγ, TNFα, and IL-1β. Then,
CardAP-EVs were investigated for their ability to interact with cardiac endothelial cells in comparison
to cardiomyocytes using well-characterized murine cells lines. To visualize the interaction, CardAP-EVs
were fluorescently labelled with DiD or PKH26. DiD labelled CardAP-EVs (CardAP-EVs DiD+) were
applied for 24 h either to cultured cardiomyocytes (HL-1 cells) or cardiac endothelial cells (MHEC5-T
cells). Both cell types were additionally treated with a DiD labelled unconditioned medium, which
served as control (DiD neg. ctrl.) to record background signals. Analysis by flow cytometry revealed
that the frequency of DiD+ HL-1 cells as well as DiD+ MHEC5-T cells (Figure 1a,b) increased over
the time period, while the DiD negative controls had very low or undetectable levels of DiD. After
24 h, nearly all HL-1 cells (mean = 89% DiD+ HL-1 cells) as well as MHEC5-T cells (mean = 94% DiD+
MHEC5-T cells) displayed a DiD+ signal indicating an uptake of DiD+ CardAP-EVs. Additionally,
the interaction was visualized by fluorescence microscopy. Here, HL-1 cells were labelled with DiD,
while CardAP-EVs and the negative control were labelled with PKH26. In accordance with the flow
cytometry results, an increase in the CardAP-EVs PKH26+ signal was detected over the time period of
24 h (Figure S1). After 24 h, some HL-1 cells showed an accumulation of separate single PKH26+ signals
for CardAP-EVs in the proximity of their nucleus, while other cells displayed no signal (Figure S1).
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Figure 1. CardAP-EVs (EVs from cardiac derived adherent proliferating cells) interact equally with
cardiomyocytes and cardiac endothelial cells. DiD labelled CardAP-EVs (CardAP-EVs DiD+) as well
as a DiD negative control (DiD neg. ctrl.) were applied to cultured HL-1 cells or MHEC5-T cells
(2 × 105 cells/well). At different time points (0, 2, 7, 19, and 24 h) cells were washed twice with PBS,
harvested and labelled with a dead/viable marker (V510) for 20 min and fixed with 0.5% PFA after
a washing step. All samples were analyzed by flow cytometry at the Canto II. (a): Representative
dot plots are shown for different time points of HL-1 cells (upper raw) as well as for MHEC5-T cells
(lower raw) treated with CardAP-EVs or treated for 24 h with the control. (b): The frequency of DiD+
HL-1 cells (right, n = 4, 4 different CardAP donors) and DiD+ MHEC5-T cells (left, n = 4–6, 3 different
CardAP donors) is shown in relation to the time of incubation (h) as median with interquartile range
for treatment with either CardAP-EVs (blue) or control (black).
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2.2. CardAP-EVs are Predominantly Internalized by Cardiomyocytes and Cardiac Vascular Cells
In a next step, it was analyzed in more detail how CardAP-EVs interact with cells. Several
possibilities can be envisioned, including an intracellular uptake of the EVs, binding of the EVs to
the cell surface or even a fusion of the EVs with the plasma membrane of the cell. The results from
the microscopic evaluation indicated that CardAP-EVs are taken up intracellularly by HL-1 cells.
To determine if CardAP-EVs were in fact intracellular, we implemented a novel method in EV research
to discriminate between intracellular and surface bound CardAP-EVs. Here, murine cells (HL-1 and
MHEC5-T) were treated for 24 h with CardAP-EVs. Since our isolated CardAP-EVs are derived
from a human source, antibodies against human proteins would only bind proteins of CardAP-EV
origin. Flow cytometry was used to detect whether EVs were localized either intracellularly or on
the surface of murine cells by two parallel performed staining protocols. When murine cells were
treated for 24 h with either unstimulated (CardAP-EVs) or cytokine stimulated (CardAP-EVs(cyt))
CardAP-EVs, the human tetraspanin CD63 was predominantly detected rather intracellularly than
on the cell surface (Figure 2a,b). Likewise, other human proteins, like another tetraspanin (CD81) as
well as 5’-nucletoidase (CD73), were also found to be mainly intracellularly rather than extracellularly
localized (Figure S2). Importantly, no unspecific antibody binding was detected for untreated murine
cells or for the isotype control staining (Figure 2a,b and Figure S2). Additionally, the presence of these
and other human markers, like integrin β-1 (CD29) and another tetraspanin (CD9), was verified for
CardAP-EVs themselves by flow cytometry (Figure 2c). A Golgi matrix protein (golgin subfamily A
member 2; GM-130) was incorporated into the analysis to rule out possible cell organelle contaminations
in the CardAP-EV samples. GM130 was not detectable in neither unstimulated nor cytokine stimulated
CardAP-EV preparations (Figure 2c), arguing against any contamination by cell organelles. Contrarily,
GM130 was determined in the apoptotic body fraction collected during EV isolation, which served as
positive control for the presence of organelles (Figure S2).
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Figure 2. CardAP-EVs are internalized by cardiac murine cells. Human CardAP-EVs either
unstimulated (CardAP-EVs) or cytokine stimulated (CardAP-EVs(cyt)) were applied to cultured murine
HL-1 cells or MHEC5-T cells (2 × 105 cells/well). Additionally, an untreated murine cell control was
included. After 24 h, these cells were harvested and stained with anti-human fluorescently labelled
antibodies for CD63, using either an intracellular or a cell surface staining protocol. Stained samples
were measured by flow cytometry at the Canto II. (a): Representative histograms are shown for HL-1
cells (upper row) and MHEC5-T cells (lower row) for human CD63 via intracellular (left) or surface
(right) staining in comparison to untreated and isotype control (EVs + isotype ctrl.) (b): The mean
fluorescent intensity (MFI) for human CD63 was normalized to an unstained control (intracellular
or surface staining) and the normalized MFI is shown as median with interquartile range for both
staining conditions as well as different treatments for HL-1 cells (left, n = 4, 3 different CardAP donors)
and MHEC5-T cells (right, n = 5, 3 different CardAP donors). (c): The presence of human markers
(CD9, CD81, CD63, CD73, CD29) and the Golgi matrix protein (GM-130) on CardAP-EVs was verified
by flow cytometry of EVs bound to sulfate/aldehyde beads. The normalized MFI are shown for all
markers as median with interquartile range (n = 3–4, 3 different CardAP donors). Statistical analysis
was performed by Kruskal-Wallis test (with Dunn’s post hoc test; * p < 0.05).
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2.3. Unstimulated and Cytokine Stimulated CardAP-EVs Enhance Angiogenesis of HUVECs by Altering Their
Release of Different Pro-Angiogenic Cues
It was already shown that the conditioned medium of CardAP cells increases the tube formation
capabilities of HUVECs [35]. To investigate if CardAP-EVs are playing a role in this paracrine mediated
pro-angiogenic effect, a Matrigel-based tube formation assay was performed. HUVECs were treated
24 h prior to the assay with either unstimulated or cytokine stimulated CardAP-EVs, PBS as EV
vehicle control or they were left untreated. The next day, the pre-treated HUVECs were seeded to
Matrigel-coated wells and observed for the next 20 h by light microscopy. Treatment with either
unstimulated or cytokine stimulated CardAP-EVs enhanced the tube formation capabilities of HUVECs
as shown in representative images (Figure 3a). The total tube length and the number of junctions was
significantly increased in HUVECs treated with either unstimulated or cytokine stimulated CardAP-EVs
in comparison to the PBS control (Figure 3b). Interestingly, unstimulated CardAP-EVs showed a trend
towards a greater pro-angiogenic effect than their cytokine stimulated counterparts. Furthermore, a
positive control (HUVECs treated with pro-angiogenic VEGF) significantly increased the total tube
length as well as the number of junctions in comparison to untreated HUVECs (Figure 3c,d).
A 24-h pre-incubation was performed prior to a Matrigel-based tube formation assay to allow time
for interactions to occur between HUVECs and CardAP-EVs. Indeed, the interaction was verified by
analysis of HUVECs that incubated with DiD labelled CardAP-EVs (median ≥ 96.7% DiD+ HUVECs,
Figure 4a,b). To evaluate pro-angiogenic factors released by HUVECs, we washed and applied fresh
medium to those pre-incubated HUVECs for another 24 h. Interestingly, HUVECs changed the released
amount of pro-angiogenic factors due to treatment with either unstimulated or cytokine stimulated
CardAP-EVs. Unstimulated CardAP-EVs significantly increased the release of VEGF and IL-6 in
comparison to PBS-treated HUVECs, whereas cytokine stimulated CardAP-EVs did not affect VEGF,
but significantly increased the secretion of IL-6 and IL-8 from HUVECs (Figure 4c).
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Figure 3. Tube for ation ca ili t sti ulated and cytokine
stimulated . 24 h prior to an assay, HUVECs w re treated with 6 µg/mL of
either unstimulated (CardAP-EVs) or cytokine stimulated CardAP-EVs (CardAP-EVs(cyt)), PBS in
cor esponding volumes of ard P- s, . The next day, HUVECs were harvested
and applied to a atrigel-coate ll a positive control, HUVECs were treated in parallel
with 10 ng/mL VEGF. The tube for ati li t icroscopy and pictures were
analyzed with the help of the ImageJ Angiogenesis Plugin. (a): Representative pictures are shown
for HUVECs treated with PBS, unstimulated and cytokine stimulated CardAP-EVs with a scale bar
representing 500 µm. (b): The quantitative analysis of the tube formation shows a significant increase
of the total branching length (upper graph) and the number of junctions (lower graph) for unstimulated
as well as cytokine stimulated CardAP-EVs. Individual data points are shown and summarized as
median with interquartile range (n = 16, 6 different CardAP donors). (c): Representative pictures are
shown for HUVECs without any treatment (un) or for HUVECs treated with 10 ng/mL VEGF (pos.
ctrl.). The scale bar represents 500 µm. (d): The total branching length (upper graph) as well as the
number of junctions (lower graph) is significantly increased by the application of VEGF versus the
untreated samples. Individual data points are shown and summarized as median with interquartile
range (n = 17). Statistical analysis for three groups was performed by repeated measures ANOVA
(Bonferroni post hoc test, *** p < 0.001, * p < 0.05). Statistical analysis of two groups was performed by
paired T test (*** p < 0.001, ** p < 0.01).
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Figure 4. The interaction of unstimulated and cytokine stimulated CardAP-EVs with HUVECs triggers
the release of different pro-angiogenic factors. Cultured HUVECs (1.9 × 105 cells/well) were treated
with DiD labelled CardAP-EVs or with a DiD negative control. After 24 h, HUVECs were washed twice
with PBS, harvested, and labelled with a dead/viable marker (V510) for 20 min and fixed with 0.5% PFA
after a washing step. All samples were analyzed by flow cytometry at the Canto II. (a): Representative
histograms are shown for HUVECs treated with the DiD negative control (DiD neg. ctrl.), DiD labelled
unstimulated CardAP-EVs (CardAP-EVs DiD+) or cytokine stimulated CardAP-EVs (CardAP-EVs(cyt)
DiD+) (b): The frequency of DiD+ HUVECs (n = 6–13, 4 different CardAP donors) is shown as median
with interquartile range for the three different treatments. (c): HUVECs were treated with 6 µg/mL of
either unstimulated (EVs), cytokine stimulated CardAP-EVs (EVs(cyt)) or PBS in volumes corresponding
to that of the CardAP-EVs. The next day, HUVECs were washed twice and fresh medium was applied
for 24 h. Then, the medium was collected for detecting IL-6, IL-8, and VEGF by ELISA. The cell
correction factor was determined by crystal violet staining. The cytokine concentrations in relation to
the cell numbers are shown for VEGF (n = 4, 4 different CardAP donors), IL-6, and IL-8 (both n = 7, 4
different CardAP donors) as median with interquartile range. Statistical analysis was performed by
Friedman test (with Dunn’s post hoc test; *** p < 0.001, ** p < 0.01, * p < 0.05).
2.4. Unstimulated and Cytokine Stimulated CardAP-EVs Differ in Their miRNA Profile
The miRNA profile of unstimulated and cytokine stimulated CardAP-EVs from three different
CardAP donors was accessed by nCounter® Human v3 miRNA expression assay (NanoString
Technologies) to better understand the differently induced pro-angiogenic factors. This assay allows
one to determine the expression level of nearly 800 human miRNAs. After background correction and
median normalization, a total of 205 miRNAs were detected in CardAP-EVs, 104 miRNAs were found
Int. J. Mol. Sci. 2019, 20, 6363 10 of 20
in both CardAP-EV populations, whilst 87 miRNAs were found exclusively in cytokine stimulated
CardAP-EVs and 14 miRNAs exclusively in unstimulated CardAP-EVs (Figure 5a). Further examination
of all miRNAs by FunRich analysis revealed that they are involved in processes of signal transduction,
cell communication or unknown biological processes (top three, Figure 5b). Five miRNAs, listed in
Table 1, were selected due to their role in angiogenesis and verified by qPCR analysis. The relative
expression for miRNA 302d-3p was significantly enhanced in unstimulated CardAP-EVs related to
the cytokine stimulated counterparts. This verifies the results of the nCounter® miRNA expression
assay results, where miRNA 302d-3p was found to be the most enriched miRNA in unstimulated
CardAP-EVs in comparison to the cytokine stimulated CardAP-EVs. In contrast, the relative expression
level for miRNA 494-3p was significantly diminished in unstimulated CardAP-EVs, which indicated
an enhanced expression in the cytokine stimulated CardAP-EVs (Figure 5c). Surprisingly, miRNA
494-3p was also detected in unstimulated CardAP-EVs by qPCR, since this miRNA was determined by
nCounter® miRNA expression assay solely in the cytokine stimulated CardAP-EVs.
Figure 5. Different composition of miRNAs between unstimulated and cytokine stimulated CardAP-EVs.
RNA was isolated from unstimulated and cytokine stimulated CardAP-EVs and used for nCounter®
miRNA expression assay as stated in the materials and methods section. (a,b): The derived data was
normalized and used for further analysis by FunRich Analysis for a comparison of observed miRNAs
between both conditions illustrated as Venn diagram (a) or as general analysis of observed miRNAs
for their involvement in biological processes as displayed as pie chart for the top eight processes
(b). (c): Five miRNAs (miR302d, miR186-5p, miR146a-5p, miR132-3p, and miR494-3p) identified in
the global nCounter® miRNA expression analysis, were validated by qPCR. Values of unstimulated
CardAP-EVs were normalized to the cytokine stimulated CardAP-EVs (set to 1, black dotted line) by
means of ∆∆Ct analysis. The relative expression is shown as median with interquartile range (n = 8–9,
3 different CardAP donors). Statistical analysis was performed with a Wilcoxon signed rank test
(** p < 0.01, * p< 0.05).
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Table 1. Involvement of selected miRNAs differently detected between both CardAP-EV populations by
nCounter® miRNA expression assay in angiogenesis. RNA of CardAP-EVs was analyzed by nCounter®
miRNA expression assay for both EV generation conditions (unstimulated and cytokine stimulated)
from three different CardAP donors. The normalized and background subtracted results for the
median counts were used to calculate the fold change between both conditions (unstimulated/cytokine
stimulated, =1.0 no difference between each other, >1 increased in unstimulated CardAP-EVs, <1
decreased in unstimulated CardAP-EVs, =0.00 just detectable in cytokine stimulated CardAP-EVs).
VEGF = vascular endothelial growth factor, HUVECs = human umbilical vein endothelial cells, ECs
= endothelial cells, RASA1 = Ras P21 protein activator1, PDGFRA = platelet derived growth factor
receptor alpha.
MiRNAs Fold Change CardAP-EVs toCardAP-EVs(cyt) Involvement in Angiogenesis
302d-3p 3.03 Pro-angiogenic, HUVECs increase VEGFrelease [41]
186-5p 1.13 Unknown
132-3p 0.61 Pro-angiogenic, suppresses GTPaseactivating proteins RASA1 [42]
146a-5p 0.39
Pro-angiogenic, ECs increase PDGFRA
expression [43] and MSCs increase VEGF
release [44]
494-3p 0.00 Contradictory roles, pro-angiogenic [45]as well as anti-angiogenic [46]
3. Discussion
There is a need to identify mechanisms by which EVs modulate angiogenesis to either optimize
their features promoting tissue regeneration or to evolve strategies limiting their pathological role in
tumor development. In order to harness their therapeutic potential, it is important to understand
how EVs interact with endothelial cells and what they carry to regulate angiogenesis. Since the
function of EVs can be strongly influenced by the microenvironment they experience during their
biogenesis [32,47], we modulated the milieu of well-characterized regenerative cardiac cells to gather
insights into how those changes might affect the pro-angiogenic features of their released EVs. For
this purpose, CardAP cells were cultured in the presence or absence of pro-inflammatory cytokines.
The medium obtained under both conditions was used to isolate CardAP-EVs, which were then
compared for their impact on cytokine or growth factor secretion and tube formation capabilities of
endothelial cells.
Isolated CardAP-EVs from both unstimulated and cytokine stimulated sources acted as potent
inducers of angiogenesis as observed by the significantly enhanced number of junctions and total
branching length of HUVECs in Matrigel-based tube formation assays. Additionally, we observed an
increased release of pro-angiogenic factors by HUVECs after their treatment with unstimulated or
cytokine stimulated CardAP-EVs. Surprisingly, this pro-angiogenic effect was induced by the release
of different pro-angiogenic cytokines. Unstimulated CardAP-EVs mediated a significant increased
release of VEGF and IL-6 by HUVECs, whereas cytokine stimulated CardAP-EVs triggered a significant
enhanced release of IL-6 and IL-8. All three factors have already been described as pro-angiogenic
inducers [48,49] as well as being involved in the pro-angiogenic features of EVs [27]. Yet, it was not
shown that differently stimulated EVs, either from cardiac cells or from MSCs, caused those different
release profiles of pro-angiogenic factors by HUVECs. As other factors were not investigated in this
study, it cannot be ruled out that CardAP-EVs also affect other mediators of angiogenesis, like the
epidermal growth factor or the platelet-derived growth factor, which could contribute to an enhanced
tube formation capability as well [27,50].
In our previous investigation of unstimulated and cytokine stimulated CardAP-EVs, some
proteins transported by CardAP-EVs were already identified to be involved in angiogenesis [40].
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One such protein identified by mass spectrometry was galectin-1, which was observed on both
unstimulated and cytokine stimulated CardAP-EVs. This carbohydrate-binding protein is known
to possess pro-angiogenic features, which also contributes to its involvement in the progression of
tumorigenesis [51–53]. As galectin-1 expression was not changed between unstimulated and cytokine
stimulated CardAP-EVs in the previous study, the currently observed differences in the increase of
angiogenesis might be due to other transported molecules. Therefore, a broad miRNA screening
was performed with the help of an nCounter® miRNA expression assay (NanoString Technologies).
Unstimulated CardAP-EVs carried a higher copy number of miRNA302d-3p in comparison to cytokine
stimulated CardAP-EVs, which was additionally verified by qPCR. Others have shown that this miRNA
stimulated HUVECs to release more VEGF as well as to increase their tube formation capabilities in
comparison to untreated controls [41]. Additionally, this group demonstrated that the pro-angiogenic
potential of miRNA302-3p was abolished in inhibition experiments using siRNA and other inhibitors
of the involved pathway. It is very intriguing to link the amplified release of VEGF by HUVECs
treated with unstimulated CardAP-EVs to the enhanced occurrence of transferred miRNA302-3p in
exactly that CardAP-EV population. However, it is unlikely that this single miRNA is exclusively
responsible for the observed pro- angiogenic effect. Other miRNAs have also been described to be
important for the support of angiogenesis, including miRNA 125a, miRNA 214, miRNA 126, miRNA
210, miRNA 132, and miRNA 146a [6,42–44]. Interestingly, we also detected miRNA 146a-5p and
miRNA 132 to be present in unstimulated as well as cytokine stimulated CardAP-EVs by nCounter®
miRNA expression assay as well as by qPCR. Additionally, we detected another miRNA candidate
regulating angiogenesis. MiRNA 494 was shown to be enriched in cytokine stimulated CardAP-EVs as
determined by nCounter® miRNA expression assay and qPCR. There are contradictory reports on the
function of this miRNA, since it has been shown to have both enhancing [45] and inhibitory [46] effects
on angiogenesis.
Since miRNAs influence the transcription of proteins, they have to be transported into a cell to be
effective. Consequently, their transporting vehicle, in this case the CardAP-EVs, have to be internalized.
We have shown that cells internalize CardAP-EVs after 24 h by performing a commonly used method
for intracellular staining for cytokines or transcription factors. We incubated CardAP-EVs, originating
from a human cell source, with two different murine cardiac cell types and determined the intracellular
and extracellular occurrence of human markers. The presence of these markers on CardAP-EVs was
verified in advance. The detection of tetraspanins (CD9, CD63, CD81), a characteristic adhesion
molecule (CD29) as well as the absence of GM130 would fulfill the requirements for EVs according
to the existing guidelines [11,54,55]. The intra-/extracellular staining method was used for the very
first time, to our knowledge, in the context of analyzing the EV uptake and interaction with cells.
Admittedly, this method cannot elucidate the efficiency of EV uptake and is highly dependent on the
present markers on investigated EVs. However, it enables an easy method to determine intracellular
uptake of EVs and can complement the current used methods.
Other studies identified the interaction with recipient cells by tracking and determining the signal
of fluorescently labelled EVs [56–58]. In the present study, we labelled CardAP-EVs with DiD or
PKH26 and observed a constant increase of DiD+ cells over 24 h by flow cytometry. Interestingly,
the interaction was independent of the cell species as murine and human cells showed comparable
CardAP-EV interaction. A control for the dye was incorporated in the study, because dyes can form
vesicle-like compartments and cause false positive signals [57]. The fluorescence control showed a
negligible signal after 24 h incubation with murine or human cells. This emphasizes that the observed
shift of fluorescence is due to the interaction of CardAP-EVs with those cells and hence a true positive
result. Additionally, we observed PKH26 fluorescently labelled CardAP-EVs in close proximity to host
cell nuclei, which is likely caused by an intracellular location of CardAP-EVs that was determined by
the intra-/extracellular staining. We speculate that the intracellular uptake of CardAP-EVs and their
localization close to the nucleus are important for the function of carried miRNAs.
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In conclusion, we have shown that EVs from cardiac cells are able to support angiogenesis.
However, differences were discovered between EVs from unstimulated and cytokine stimulated cardiac
cells in regard to their miRNA composition, which seems to be connected with the provoked release of
different pro-angiogenic factors after their internalization into endothelial cells. This new insight allows
now for a selection of potent targets to develop a more efficient and safe therapeutic intervention.
4. Materials and Methods
4.1. Isolation of Human CardAP Cells
Human CardAP cells were generated by outgrowth cultures of endomyocardial biopsies from the
right or left ventricular side of the interventricular septum as previously described [38]. Tissues were
obtained according to the local guidelines of the Charité-Universitätsmedizin Berlin and the study was
approved on 14th November 2016 by the ethics committee of the Charité-Universitätsmedizin Berlin
(No. EA2/140/16).
4.2. Cell Culture of Primary Cells and Cell Lines
In general, cryopreserved cells were thawed and cultured in the appropriate media for at least one
passage till usage. HL-1 cells were cultured in Claycomb medium (Sigma-Aldrich, St. Louis, MO, USA)
supplemented with 10% fetal bovine serum (Biochrom, Berlin, Germany), 1% penicillin/streptomycin,
2 mM glutamine (all provided by Gibco® Life Technologies, Grand Island, NY, USA) and 100 µM
norepinephrine (Sigma, Steinheim, Germany). MHEC5-T cells were cultured in DMEM (Biochrom,
Berlin, Germany), and supplemented with 1% penicillin/streptomycin, 10% fetal calf serum and
2 mM L-glutamine. For the culture of CardAP cells and human umbilical vein endothelial cells
(HUVECs, purchased from Cascade Biologics®, Thermo Fisher Scientific, Rochester, NY, USA) the
human serum (German Red Cross, Berlin, Germany) was ultracentrifuged (UC serum) to avoid
contamination of extracellular vesicles (EVs) by the serum source. Therefore, medium supplemented
with 50% human serum was centrifuged for 24 h at 100,000× g (L7-55 ultracentrifuge with SW-32
Ti buckets; all from Beckman coulter, Palo Alto, CA, USA). CardAP cells were cultured in IDH
medium (equal amounts of IMDM/DMEM/Ham´s F12; all Biochrom) supplemented with 10% UC
serum, 1% penicillin/streptomycin, 20 ng/mL basic fibroblast growth factor and 10 ng/mL epithelial
growth factor (both from Preprotech, Hamburg, Germany). HUVECs were cultured in EBM medium
(Lonza, Walkersville, MD, USA) supplemented with 10% UC serum, 1% penicillin/streptomycin, 2 mM
L-glutamine and most supplements of the EGM-2 BulletKit (Lonza, Walkersville, MD, USA). Here, the
fetal calf serum was not supplemented, since the UC serum was used for cultivation. Unless stated
otherwise, primary cells were used in all in vitro assays from passage 2 to 7.
4.3. Isolation and Characterization of CardAP-EVs
CardAP-EVs were isolated by differential centrifugation as recently described [40]. Briefly,
conditioned medium was collected from 80% confluent CardAP cells, which had been incubated
for 20 h in serumfree IDH medium either in the presence or absence of 10 ng/mL of human TNFα,
human IFNγ and human IL-1β (all purchased from Miltenyi Biotec, Bergisch Gladbach, Germany).
The conditioned medium then underwent a stepwise centrifugation at 300× g for 10 min, at 2000×
g for 20 min, at 12,000× g for 45 min and at 100,000× g for 165 min (Allegra® X-15R centrifuge and
L7-55 ultracentrifuge with SW-32 Ti buckets; all from Beckman coulter, Brea, CA, USA). The last
centrifugation step was repeated to wash the EV pellet with 0.1 µm filtered PBS (Biochrom, Berlin,
Germany) For dye labelling CardAP-EVs, EVs were incubated with either 6 µL Vybrant® DiD cell label
solution (Invitrogen™, Molecular Probes, Eugene, OR, USA) or 3 µL PKH26 (PKH26 Red Fluorescent
Cell Linker Kits for General Cell Membrane Labelling, Sigma Aldrich, St. Louis, MO, USA) in 6 mL PBS
for 10 min on ice prior to the final centrifugation step. A negative control for labelling was processed in
the same way by labelling unconditioned serumfree IDH medium to exclude false positive staining by
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DiD or PKH26 aggregates. All samples were reconstituted in 500 µL of 0.1 µm filtered PBS, transferred
to low-binding tubes (Sarstedt, Nümbrecht, Germany) and stored at −80 ◦C till further usage.
All batches of isolated CardAP-EVs were analyzed for their protein content by Pierce™ BCA
protein assay (Thermo Scientific, Rockford, IL, USA) and investigated for surface marker by flow
cytometry as previously described [40]. In this study, CardAP-EVs coupled to 4 µm aldehyde/sulfate
beads (Molecular Probes®, Life Technologies, Eugene, OR, USA) were additionally tested for the
presence of GM130. Therefore, CardAP-EVs bound to beads were washed in FACS buffer (1% fetal calf
serum in PBS) and then stained for 30 min with the anti-GM130/GOLGA2 antibody (Novius Biologicals,
Abingdon, UK). Afterwards, the samples were washed, incubated in FACS buffer containing rabbit
serum (Sigma AldrichSt. Louis, MO, USA) for 15 min and afterwards stained for 30 min with an
anti-rabbit AF488 labelled antibody (Molecular Probes, Eugene, OR, USA). Finally, the samples were
washed, fixed in 0.5% PFA supplemented FACS buffer and stored at 4 ◦C until measurement on a
MACSQuant (Miltenyi Biotec, Bergisch Gladbach, Germany). Additionally, staining controls were
included for the secondary antibody (anti-rabbit AF488; negative control) alone as well as apoptotic
beads bound to aldehyde/sulfate beads (positive control).
4.4. Interaction Studies of Labelled CardAP-EVs with Different Recipient Cells
Murine HL-1 or MHEC5-T cells were cultured in a 48-well-plate (2 × 105/well) and treated either
with 6 µg DiD labelled CardAP-EVs or the equal volume of DiD negative control. Cells were harvested
at different time points (0, 2, 7, 19, and 24 h) for analysis by flow cytometry. Cells were washed twice
with PBS and harvested by Accutase (Gibco®, Life Technologies) treatment. Afterwards, the cells were
labelled in FACS buffer with a dead/viable marker (V510, 1:100; LIVE/DEAD® Fixable Aqua Dead
Cell Stain Kit; Invitrogen/Thermo Fisher Scientific, Eugene, OR, USA) for 20 min, washed with FACS
buffer and fixed with 0.5% PFA supplemented FACS buffer. All samples were measured at the Canto II
(BD Biosciences, Heidelberg, Germany) and all flow cytometry data were analyzed with FlowJo 10.2.
Software (FlowJo™, LLC, RO, USA).
Microscopic analysis was performed to visualize the interaction between labelled CardAP-EVs
and recipient cells. DiD labelled HL-1 cells were cultured in a 48-well-plate (2 × 105/well) and treated
with 6 µg PKH26 labelled CardAP-EVs or the equal volume of the PKH26 negative control. The
interaction was stopped at different time points (0, 2, 7, 19, and 24 h). Here, cells were washed with
PBS, fixed with 4 % PFA in PBS and afterwards labelled with 4´,6-diamidino-2-phenylindole (DAPI;
Molecular Probes®, Life Technologies, Waltham. MA, USA). After two washing steps, cells were
examined in 20× magnification with the help of an AxioObserver microscope running AxioVision
software (both from Carl Zeiss Microscopy GmbH, Jena, Germany).
4.5. Combined Intra- and Extracellular Staining to Monitor Interaction of CardAP-EVs with Recipient Cells
The interaction of CardAP-EVs with murine cells was assessed by evaluating human CardAP-EV
markers within or on murine cells by an intra- or extracellular staining. HL-1 or MHEC5-T cells were
cultured in a 48-well-plate (2 × 105/well) and treated with 6 µg CardAP-EVs either unstimulated or
cytokine stimulated, or they were left untreated. Cells were harvested after 24 h by Accutase treatment,
evenly distributed into at least two 5 mL Polystyrene Round-Bottom Tubes (Falcon®, Corning Science
México, Tamaulipas, Mexico) and washed once in FACS buffer. For the extracellular staining (surface
staining), both murine cell types were stained for 30 min in the dark with human-specific antibodies for
CD73-APC, CD63-PE and CD81-FITC, (all 1:50 and purchased from Biolegend, San Diego, CA, USA)
and a dead/viable marker as previously stated. The intracellular staining for the listed human markers
was done according to the manual of Foxp3/Transcription Factor Staining Buffer Set (Invitrogen by
Thermo Fisher Scientific, Carlsbad, CA, USA). Firstly, cells were stained for the viability marker as
stated beforehand. Secondly, cells were permeabilized with the provided Fix/Perm solution. Finally,
these cells were stained intracellularly with the same antibodies used for the extracellular stain except
the dead/viable marker. Afterwards, labelled cells were washed and fixed with 0.5% PFA until
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measurement at the Canto II. Controls included untreated cells stained with the anti-human antibodies
as well as CardAP-EV treated cells stained with isotope control antibodies (mouse IgG1, kappa APC
for CD73 APC, purchased from Miltenyi, mouse IgG1, kappa PE for CD63 PE, mouse IgG1, kappa
FITC for CD81 FITC, both purchased from Biolegend).
4.6. Matrigel Based Tube Formation Assay
HUVECs were seeded in 6-well plates (1.9× 105/well) 24 h prior to a Matrigel-based tube formation
assay. They were treated with 6 µg/mL of either unstimulated or cytokine stimulated CardAP-EVs, PBS
in equal volumes to EVs or were left untreated. The next day, HUVECs were harvested by Accutase
treatment and used for Matrigel-based tube formation assays. Pre-cooled 24-well plates were coated
with 200 µL Matrigel (Corning) per well. The plates remained on ice until the transfer for 30 min to
37 ◦C with 5% CO2 to allow the gel to set. Afterwards, each well was washed with PBS before adding
1 × 105 HUVECs in 400 µL EBM medium. A positive control was included by adding 10 ng/mL VEGF
(Miltenyi) to untreated HUVECs. Furthermore, each condition was performed in duplicates and the
network formation of the tubular structures was documented after 20–24 h with an AxioObserver
microscope running AxioVision software (both Carl Zeiss Microscopy, Jena, Germany). Eight random
images were taken for each sample and quantified for the tubular network formation (number of
junctions and total branching length) by performing analysis with the Angiogenesis Analyzer plugin
for the free available software ImageJ1.50i (Wayne Rasband, NIH, USA).
4.7. Detection of Pro-Angiogenic Factor Release in HUVEC Cultures
Supernatants of treated HUVECs were analyzed for human VEGF (Quantikine® ELISA, R&D
Systems, Biotechne brand, Mineapolis, MN, USA), IL-6 and IL-8 (both ELISA MAX™Deluxe; Biolegend)
using an enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s protocol.
In brief, ELISA microplates (Nunc™ MaxiSorp™ ELISA Plates, Uncoated, Thermo Fisher Scientific,
Rochester, NY, USA) were coated overnight with the capture antibody (1:200) and followed by several
washing steps using PBS + 0.05% Tween 20 (Sigma Aldrich, St. Louis, MO, USA) on the next day.
Microplates were blocked with the blocking buffer for at least 3 h. Next, samples and freshly prepared
standards were added to the wells for an overnight incubation. On the next day, the plates were
washed several times and the detection antibody (1:200) was applied for additional 2 h. After washing,
the avidin-HRP conjugate (1:1000) was added to each well and washed away after 1 h by thorough
washing. Fresh TMB substrate was added to the wells and incubated for 15–20 min. The reaction
was stopped with stop solution and the absorbance was measured at 450 nm and 570 nm on a plate
reader (Mithras LB 940 and MikroWin Version 4.41 software, both from Berthold Technologies, Bad
Wildbad, Germany). For normalization to the cell amount, HUVECs were stained with crystal violet
(Merck Chemicals, Darmstadt, Germany) and the absorbance was measured at 495 nm on the same
plate reader as the ELISAs. Data are represented as the ration of the ELISA results towards the crystal
violet determination.
4.8. Extraction and Expression Analysis of miRNAs from CardAP-EVs
MiRNA was extracted from CardAP-EVs after the final centrifugation step by using the miRNeasy
Mini Kit (Qiagen, Valencia, CA) according to manufacturer’s instructions. The RNA eluate was
evaluated for its concentration with the NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific,
Waltham, MA, USA). An overview of the miRNA content was achieved by performing an analysis with
the nCounter® Analysis System (NanoString Technologies, Seattle, WA, USA). MiRNA isolates from
each condition of three different CardAP donors were investigated with the help of the nCounter®
Human v2 miRNA expression assay panel, according to the manufacturer’s protocol (NanoString
Technologies) at an nCounter® Digital Analyzer. Analysis of the gathered raw data for miRNAs
was performed with nSolver software (version 4.0, NanoString Technologies, Seattle, WA USA,
http://www.NanoString.com/products/nSolver). Therefore, the data was normalized using the top 100
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most abundant miRNAs in all samples as well as the positive controls to normalize for any differences in
preparation, hybridization, and processing efficiency. Normalized miRNA counts were used for further
analysis and a background correction was used by subtracting the mean + 2 standard derivations of
negative control. Afterwards, a count of 10 or more copy numbers was used to define the presence of a
given miRNA in CardAP-EVs. Furthermore, at least two of the three donors had to display the miRNA
to be considered for further analysis. This normalized data was further investigated for enrichment in
biological pathways and in comparative Venn diagram by an open-source software called Functional
Enrichment Analysis Tool (FunRich, version 3.1.3, http://www.funrich.org) [59,60].
Additionally, some miRNAs were evaluated by quantitative poly chain reaction (qPCR). Therefore,
the 10 ng of RNA was reverse transcribed with TaqMan® Advanced miRNA cDNA Synthesis Kit and
used for PCR reaction with TaqMan® Fast Advanced Master Mix, all according the manufacture´s
protocol. The qPCR was performed on a QuantStudio 6 Flex Real-Time PCR machine (Applied
Biosystems, Thermo Fisher Scientific, Darmstadt, Germany). Three technical replicates of each
sample were analyzed for gene expression for the following human miRNAs: 494-3p,146a-5p, 132-3p,
26b-5p, 199a-3p, 186-5p, and 302d-3p (purchased as TaqMan® Advanced miRNA Assay; all from
Applied Biosystems, Thermos Fisher). The samples were normalized to the expression of the median
of miRNA26b-5p and miRNA199a-3p, which were identified to be the most stable in CardAP-EV
preparations by NormFinder Excel Add-In v0.953 [61]. The data was analyzed with the delta-delta
CT (∆∆ CT) method. Therefore, the final results were calculated as fold change of target miRNA
expression in unstimulated CardAP-EVs relative to the cytokine stimulated CardAP-EV reference
samples to demonstrate differentially expressed miRNAs.
4.9. Statistical Analysis
All data are shown as median with interquartile range, if not indicated otherwise, and
statistical analysis was performed using GraphPad Prism 6.0 software (GraphPad Software Inc,
San Diego, CA, USA). First, data were tested with Shapiro-Wilk test for normal distribution. For the
comparison of the different groups, data were tested by repeated measures test for One-Way ANOVA.
Therefore, parametric data were tested with repeated measures ANOVA (Bonferroni post hoc test)
or non-parametric data sets were tested with Friedman test (with Dunn’s post hoc test). Statistical
differences between two groups with only one variable in paired observations were determined either
for non-parametric samples using with the Wilcoxon matched-pairs signed rank test or for parametric
samples with the paired T test. For unpaired non-parametric observations, the data were analyzed with
Kruskal-Wallis test (with Dunn’s post hoc test). Results were considered significant with * p < 0.05,
** p < 0.01, *** p < 0.001.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/24/
6363/s1.
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